Clinical ink has launched the AI-powered, fully integrated analytics dashboard, TrialLens, designed to transform the visualisation, querying, and interpretation of trial electronic clinical outcome assessment (eCOA) data.
The dashboard is designed to provide real-time insights into operations, subject behaviour, and metrics of digital biomarkers in hybrid and decentralised trials.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the company, the dashboard is built upon modern data architecture. It unites Snowflake’s data cloud and Amazon Web Services (AWS) technologies, including Q, QuickSight, and Bedrock, thereby offering access to trial insights.
Equipped with integrated generative AI prompt engineering, TrialLens allows sponsor and vendor operations teams to investigate clinical data through natural language storytelling and custom queries.
TrialLens facilitates a single view of different data sources.
Clinical ink’s global product innovation senior vice-president Steve Polyak said: “TrialLens represents a fundamental leap in how data is surfaced, interpreted, and acted upon in clinical research.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“By embedding AI natively into the analytics workflow, we’re enabling our users to move from passive reporting to predictive, proactive decision-making.”
The dashboard provides real-time analytics on subject compliance, engagement, site performance, visit adherence, and scheduling logistics through eCOA.
In addition, it enables the visualisation of subject physiological data and the status of blood glucose meters, actigraphy sensors, smart scales, and continuous glucose monitors.
Operational insights are also integrated into the dashboard, offering visibility into study logistics to support risk mitigation, trial execution, and site management.
Clinical ink’s science and innovation director David Anderson said: “Clinical trials leveraging digital health technologies generate complex, multidimensional datasets. TrialLens turns that complexity into clarity.
“We’ve designed this platform to scale across therapeutic areas and study designs while supporting the scientific rigour needed for regulatory-grade research.”
The announcement follows the introduction of EDCXtra, Clinical ink’s new electronic data capture system for trials last August.
